Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Intravenous pamidronate for myeloma bone disease: can the dose be lowered? — Evangelos Terpos (2010) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Shared by
Meletios A Dimopoulos
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
Letter
2010
en
Authors
ET
Evangelos Terpos
Meletios A Dimopoulos
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2011
What dose of intravenous immunoglobulin should be administered in Kawasaki disease with suspected systemic capillary leak syndrome?
Se Jin Park
,
Ki Soo Pai
,
Ji Hong Kim
,
Jae Il Shin
Article
2019
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Martina Kleber
,
Ioannis Ntanasis‐Stathopoulos
,
Meletios A Dimopoulos
,
Evangelos Terpos
Article
2021
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
Αριστέα-Μαρία Παπανώτα
,
Panagiotis Tsiakanikas
,
Christos K. Kontos
,
Panagiotis Malandrakis
,
Christine‐Ivy Liacos
,
Ioannis Ntanasis‐Stathopoulos
,
Nikolaos Kanellias
,
Maria Gavriatopoulou
,
Efstathios Kastritis
,
Margaritis Avgeris
,
Meletios A Dimopoulos
,
Andreas Scorilas
,
Evangelos Terpos
Article
2017
Emerging treatment approaches for myeloma-related bone disease
Maria Gavriatopoulou
,
Meletios A Dimopoulos
,
Efstathios Kastritis
,
Evangelos Terpos
Letter
2018
Denosumab for myeloma bone disease: ready for prime time?
Meletios A Dimopoulos
,
Efstathios Kastritis
Discussion(0)
No comments yet. Be the first to comment.